Lawniczak M, Jezewska E, Górny M K, Zeromski J
Neoplasma. 1985;32(1):9-20.
Pleural effusions from 15 patients with advanced primary bronchial carcinoma, from 2 patients with metastatic lung cancer and from 6 patients with nonmalignant disease were studied. Immune complexes were found in examined fluids in amounts corresponding to 2.5-210 mg/100 ml of aggregated IgG by means of ELISA solid phase anti C3 and 125ICIq binding radioimmunoassay. Following determination of protein content and salting out by ammonium sulfate of examined fluids, the sediments were subjected to subsequent chromatographic procedure including molecular sieving (Sephadex G-200, Sepharose 4B) and affinity chromatography on Protein A-Sepharose CL-4B. The yield--apparently pure immune complexes--was then split by means of chaotropic agent 2.5 M KSCN. It permitted to obtain 2 fractions: one contained IgG while the other was a non-Ig protein of m. w. = 150 000. The latter isolated from malignant effusions possessed antigenic activity in the leukocyte migration inhibition (LMI) assay. It resulted in inhibition of migration of allogenic peripheral blood leukocytes from lung cancer patients in 87% of cases. It had no activity against leukocytes from nonmalignant disease patients. LMI activity of the final second fraction derived from malignant effusion was significantly different from that of other fractions obtained both from malignant and nonmalignant fluids.
对15例晚期原发性支气管癌患者、2例转移性肺癌患者和6例非恶性疾病患者的胸腔积液进行了研究。通过ELISA固相抗C3和¹²⁵I C1q结合放射免疫测定法,在所检测的胸液中发现了免疫复合物,其含量相当于2.5 - 210毫克/100毫升聚集的IgG。在测定所检测胸液的蛋白质含量并用硫酸铵盐析后,将沉淀物进行后续的色谱分析程序,包括分子筛(葡聚糖凝胶G - 200、琼脂糖4B)和蛋白A - 琼脂糖CL - 4B亲和色谱。然后用离液剂2.5M硫氰酸钾分离得到明显纯的免疫复合物。这样可以得到两个组分:一个含有IgG,另一个是分子量为150000的非Ig蛋白。从恶性胸液中分离出的后者在白细胞迁移抑制(LMI)试验中具有抗原活性。在87%的病例中,它导致肺癌患者的同种异体外周血白细胞迁移受到抑制。它对非恶性疾病患者的白细胞没有活性。源自恶性胸液的最终第二个组分的LMI活性与从恶性和非恶性胸液中获得的其他组分的LMI活性有显著差异。